Starton is a clinical-stage biotechnology company transforming standard of care therapies with proprietary dermal delivery technology, so people with cancer can receive continuous treatment to live better, longer. Starton's strategic platform targets new indications and opportunities to replace the standard of care. Two programs entering clinical development: STAR-LLD in hematologic malignancies (blood cancers, Phase 1) and STAR-OLZ in cancer supportive care (CINV, Phase 2). The experienced Board and management team includes world-renowned scientific leaders in their field leading each program.